Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P24347
UPID:
MMP11_HUMAN
Alternative names:
Matrix metalloproteinase-11
Alternative UPACC:
P24347; Q5FX24; Q6PEZ6; Q9UC26
Background:
Stromelysin-3, also known as Matrix metalloproteinase-11, is a protein that may play a pivotal role in the progression of epithelial malignancies. Its unique structure and function distinguish it from other matrix metalloproteinases, making it a subject of intense study in the field of cancer research.
Therapeutic significance:
Understanding the role of Stromelysin-3 could open doors to potential therapeutic strategies. Its involvement in epithelial malignancies highlights its importance as a target for drug discovery efforts aimed at combating cancer.